Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr -null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [256]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158 · cited 1×
“All individuals fulfilled the following inclusion criteria: (1) no significant alcohol consumption (the definition of significant alcohol consumption has been inconsistent and ranged from 41 alcoholic beverage (10 g of alcohol per one drink unit) per day to 440 g per day); (2) no significant acute or chronic inflammat…”
BackgroundKanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Brown and beige fat: Development, function and therapeutic potential
Harms, M., & Seale, P. (2013) · Nature Medicine · doi:10.1038/nm.3361 · Cited by 2,328
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationBile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Petrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B., & Nedergaard, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053942 · Cited by 1,263
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Cited by
Items 401–500 of 566
Patented Farnesoid X receptor modulators: a review (2019 – present)
Gioiello, A., Rosatelli, E., & Cerra, B. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2314296 · Cited by 14
“Interestingly, deficiency or antagonism of intestinal FXR was found to improve obesity, insulin resistance, and nonalcoholic fatty liver disease (NAFLD) [17,18].”
BackgroundQuantifying Forms and Functions of Enterohepatic Bile Acid Pools in Mice
Sudo, K., Eliason, A. D., Soucy, S. M., Barrack, K. E., Liu, J., Balasubramanian, A., Shu, C. J., James, M. J., Hegner, C. L., Dionne, H. D., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101392 · Cited by 14
“86 – 88 The extent to which these or other competitive interactions shape host intestinal responses to BAs have yet to be rigorously examined.”
BackgroundDisentangling Organ‐Specific Roles of Farnesoid X Receptor in Bile Acid and Glucolipid Metabolism
Li, T., Fu, C., Tang, Z., Li, C., Hua, D., Liu, B., Tao, Z., Yang, J., Zhang, L., Cheng, T., et al. (2025) · Liver International · doi:10.1111/liv.70027 · Cited by 15
“Additionally, studies exploring the role of intestinal FXR in DIO using gut-specific FXR-KO models may have overlooked the metabolic consequences of potentially altered hepatic FXR PTMs after ablating gut FXR under the HFD condition [40].”
Discovery of 9,11-Seco-Cholesterol Derivatives as Novel FXR Antagonists
Zhou, J.-X., Li, C.-N., Liu, Y., Lin, S., Wang, Y., Xie, C., & Nan, F. (2022) · ACS Omega · doi:10.1021/acsomega.2c01567 · Cited by 14
Self-citationChen, C., Liu, L., Zhong, Y., Wang, M., Ai, Y., Hou, Y., Chen, H., Lin, X., Zhang, Y., Ding, M., et al. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109358 · Cited by 14
Self-citationKamiya, T., & Ohtani, N. (2022) · International Immunology · doi:10.1093/intimm/dxac020 · Cited by 12
Schmidt, J., Schierle, S., Gellrich, L., Kaiser, A., & Merk, D. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.017 · Cited by 11
Yang, D., Wei, X., Zhang, B., Zhu, R., Hu, H., Fan, X., Du, H., Chen, X., Zhang, Z., Zhao, M., et al. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113440 · Cited by 10
Zhang, D., Liu, X., Qi, Y., Lin, Y., Zhao, K., Jin, Y., Luo, J., Xu, L., Yu, D., & Li, C. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.161701 · Cited by 10
Nuclear receptors behind the therapeutic effects of plant sterols on metabolism: A review
Brañes, M. C., Gillet, R., & Valenzuela, R. B. (2024) · Lipids · doi:10.1002/lipd.12409 · Cited by 12
Precision nutrition for obesity management: A gut microbiota–centered weight-loss approach
Carvalho, L. M., da Mota, J. C. N. L., Ribeiro, A., Carvalho, B. G., Martínez, J. A., & Nicoletti, C. F. (2025) · Nutrition · doi:10.1016/j.nut.2025.112892 · Cited by 10
Bile Acids in Control of the Gut-Liver-Axis
Hild, B., Heinzow, H. S., Schmidt, H., & Maschmeier, M. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1330-9644 · Cited by 11
“The same group could expand this finding by showing that inhibition of intestinal FXR with glycine-βmuricholic acid was able improve metabolic functions in mice [62].”
BackgroundNatural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease
Wang, J., Yang, N., & Xu, Y. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500137 · Cited by 11
Li, Y., Liu, X., Sun, X., Li, H., Wang, S., Tian, W., Chen, X., Zhang, X., Zheng, J., Wang, H., et al. (2024) · Protein & Cell · doi:10.1093/procel/pwae016 · Cited by 10
Effect of Osteocyte-Ablation on Inorganic Phosphate Metabolism: Analysis of Bone–Kidney–Gut Axis
Fujii, O., Tatsumi, S., Ogata, M., Arakaki, T., Sakaguchi, H., Nomura, K., Miyagawa, A., Ikuta, K., Hanazaki, A., Kaneko, I., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00359 · Cited by 10
“Bile acids are also important signaling molecules and have a role in energy metabolism, metabolic syndrome, obesity, and diabetes (68).”
Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR)
Pierre, J. F., Li, Y., Gomes, C., Rao, P., Chang, E. B., & Yin, D. (2019) · Obesity · doi:10.1002/oby.22440 · Cited by 10
“In addition, the FXR antagonist taurine-b-muricholic acid (TbMCA) is effective in improving obesity associated metabolic parameters (21).”
BackgroundRole of intestinal microbiota in the formation of non-alcoholic fatty liver disease
Ахмедов, В. А., & Gaus, O. V. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.02.000051 · Cited by 13
“В ходе этих исследований показано, что у экспериментальных мышей на фоне данной терапии отмечались снижение экспрессии генов, участвующих в печеночном липогенезе, и низкие уровни показателей церамидов, а также отсутствовали признаки стеатоза печени [71, 72].”
Xanthohumol improves cognition in farnesoid X receptor-deficient mice on a high-fat diet
Kundu, P., Paraiso, I. L., Choi, J., Miranda, C. L., Kioussi, C., Maier, C. S., Bobe, G., Stevens, J. F., & Raber, J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049820 · Cited by 11
“FXR in the intestine regulates ceramide synthesis (Jiang et al., 2015; Xie et al., 2017).”
Yang, Z., Lin, Z., You, Y., Zhang, M., Gao, N., Wang, X., Peng, J., & Wei, H. (2024) · Advanced Science · doi:10.1002/advs.202412071 · Cited by 15
Ursodeoxycholic acid acts as an ileal FXR agonist in male mice with hepatic deficiency of FXR
Henry, Z. R., Maliha, S., Basaly, V., Yang, Z., Taylor, R. E., Otersen, K., Meadows, V., Rizzolo, D., Stofan, M., Bhattacharya, A., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100227 · Cited by 12
“18 Although controversial, these studies demonstrate tissue-restricted FXR modulation as a critical approach in the treatment of MASH and metabolic syndrome overall.”
Nuclear Receptors and Transcription Factors in Obesity-Related Kidney Disease
Jones, B. A., Wang, X. X., Myakala, K., & Levi, M. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.004 · Cited by 9
Finamore, C., Festa, C., Fiorillo, B., Leva, F. S. D., Roselli, R., Marchianò, S., Biagioli, M., Spinelli, L., Fiorucci, S., Limongelli, V., et al. (2023) · Molecules · doi:10.3390/molecules28062840 · Cited by 10
Shyng, S. (2017) · Diabetes · doi:10.2337/dbi16-0066 · Cited by 9
“(17) extend previous studies from this group documenting the effects of intestine-specific FXR inhibition on lipid and glucose metabolism through downregulation of ceramide production in the intestine by genetic deletions as well as compounds such as tempol or glycine-b-muricholic acid that cause intestine-selective F…”
BackgroundWang, S., Zhao, C., Huang, X., Gao, Y., Qiu, Y., Jiao, R., Zhu, H., Ding, H., Lin, R., & He, Z. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106466 · Cited by 9
Zhou, W., Bandara, S. R., Ko, K., Akinrotimi, O., Hernández‐Saavedra, D., Richter, E., Brauer, N., Woodward, T. J., Bradshaw, H. B., Leal, C., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100754 · Cited by 9
Bile Acids and Type 2 Diabetes: Roles in Glucose Homeostasis and Therapeutic Opportunities
Lin, Y., Hu, C., Wang, S., & Lin, H. (2025) · Metabolites · doi:10.3390/metabo15060401 · Cited by 10
“Suppression of intestinal FXR can diminish ceramide synthesis in the intestine, hence alleviating endoplasmic reticulum (ER) stress and the secretion of proinflammatory cytokines in the liver, which improves IR [41].”
Farnesoid X receptor regulators from natural products and their biological function.
Wan, P., Hengfan, N. I., Dale, G., Yun, D., & Manyun, D. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.20230404.002 · Cited by 11
FXR Friend-ChIPs in the Enterohepatic System
Meadows, V., Yang, Z., Basaly, V., & Guo, G. L. (2023) · Seminars in Liver Disease · doi:10.1055/a-2128-5538 · Cited by 9
Teno, N., Iguchi, Y., Yamashita, Y., Mori, N., Une, M., Nishimaki‐Mogami, T., & Gohda, K. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.01.040 · Cited by 9
“Thus, the synthetic and low-molecular weight FXR antagonists would be a breakthrough in existing metabolic dysfunctions.(27) In a series of nonsteroidal FXR ligands disclosed to date, several ligands share many types of heteroaromatic rings, which”
BackgroundNakatsu, G. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15715 · Cited by 10
Wang, Y., Wang, D., Chen, Y., Fang, X., Yu, L., & Zhang, C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa001 · Cited by 8
An insoluble cellulose nanofiber with robust expansion capacity protects against obesity
Yu, J. G., Gao, M., Wang, L., Guo, X., Liu, X., Sheng, M., Cheng, S., Guo, Y., Wang, J., Zhao, C., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134401 · Cited by 9
Self-citationChen, H., Xin, J., Li, Y., Guo, H., Wu, J., Li, S., Hu, F., & Xu, G. (2025) · Advanced Science · doi:10.1002/advs.202401956 · Cited by 7
Sanye tablet regulates gut microbiota and bile acid metabolism to attenuate hepatic steatosis
Qi, Y., Du, S., Li, W., Qiu, X., Zhou, F., Bai, L., Zhang, B., Mi, Z.-X., Qian, W., Li, L., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119514 · Cited by 7
Impact of intestinal microenvironments in obesity and bariatric surgery on shaping macrophages
Leyderman, M., Wilmore, J. R., Shope, T. R., Cooney, R. N., & Urao, N. (2023) · Immunometabolism · doi:10.1097/in9.0000000000000033 · Cited by 9
“In the ileum, mRNA levels of FXR and its targets, Shp and Fgf19, are rather increased in obese humans [119] , while FXR expression is reduced in offspring of maternal obesity in the kidney [120] .”
BackgroundUpdate on lipid species and paediatric nonalcoholic fatty liver disease
Mann, J. P., Feldstein, A. E., & Nobili, V. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000346 · Cited by 10
LKB1 in Intestinal Epithelial Cells Regulates Bile Acid Metabolism by Modulating FGF15/19 Production
Kim, Y., Lee, S., Kim, S., Kim, T., Lee, S.-H., Chang, J., & Kweon, M. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.12.017 · Cited by 9
“However, mice treated with an intestinal FXR inhibitor and transgenic mice overexpressing CYP7a1 had increased BA pool size and energy expenditure, and were thus were highly resistant to HFD-induced obesity.(61,62) Hence, metabolic changes in HFDfed LKB1 mice resulted from an increased BA pool size.”
BackgroundTranscriptional Control of Trpm6 by the Nuclear Receptor FXR
Kim, E. Y., & Lee, J. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041980 · Cited by 9
Host—microbial interactions in metabolic diseases: from diet to immunity
Lee, J.-H., & Park, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-2087-y · Cited by 7
“The inhibition of intestinal FXR prevents obesity-related metabolic disorders in HFD-fed mice (Li et al., 2013; Gonzalez et al., 2015; Jiang et al., 2015; Parséus et al., 2017).”
BackgroundYang, J., van Dijk, T. H., Koehorst, M., Havinga, R., de Boer, J. F., Kuipers, F., & van Zutphen, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044132 · Cited by 8
“This result was different from previous studies showing that intestinal FXR promotes hepatic lipid accumulation [22,32].”
BackgroundResultInfluentialLi, Y., Jiao, T., Cheng, X., Liu, L., Zhang, M., Li, J., Wang, J., Hu, S., Li, C., Yu, T., et al. (2025) · Life Metabolism · doi:10.1093/lifemeta/loaf004 · Cited by 6
“The discovery of GlyMCA has overcome the issue of easy metabolism by bacterial bile salt hydrolase, which affects endogenous intestinal FXR antagonists, and has shown great potency in improving obesity and insulin resistance caused by lipid accumulation [5].”
Self-citationZhang, Z., Xie, L., Lin, X., He, J., Xie, Y., Li, J., Zhuang, X., Tang, L., Xie, R., Wu, Q., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08403-2 · Cited by 7
“Recent studies have shown that intestinal FXR promotes the secretion of intestinal-derived ceramides, contributing to Non-Alcoholic Fatty Liver Disease (NAFLD), obesity, insulin resistance, and atherosclerosis 19,27,28 .”
Self-citationAl-Busaidi, A., Alabri, O., Alomairi, J., Elsharaawy, A., Lawati, A. A., Lawati, H. A., & Das, S. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998281910231231051814 · Cited by 9
Wang, J., Zheng, D., Ge, K., Huang, F., Yang, L., Zheng, X., Jia, W. P., & Zhao, A. (2024) · Food Frontiers · doi:10.1002/fft2.394 · Cited by 7
Niu, D., Wu, X., Zhang, Y., Wang, X., Chan, D. S., Jing, S., Wong, C., Wang, W., & Leung, C. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.10.028 · Cited by 7
“Previous studies showed that deletion of FXR, either in the whole body or specifically in the intestine, improved metabolism in obese mouse models, and reduced hyperglycemia and steatosis [11,12,38].”
Endogenous Metabolites in Metabolic Diseases: Pathophysiologic Roles and Therapeutic Implications
Xiao, M., Zhou, N., Tian, Z., & Sun, C. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.04.017 · Cited by 6
Targeting Bile Acid-Activated Receptors in Bariatric Surgery
Ding, L., Fang, Z., Liu, Y., Zhang, E., Huang, T., Yang, L., Wang, Z., & Huang, W. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_229 · Cited by 6
Self-citationYang, H.-C., Wang, G.-J., Xia, Y. L., Tian, J., Xie, J. H., Zhang, K., Li, Z., Yu, E., Li, H.-Y., Gong, W., et al. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.101988 · Cited by 7
Zhi, H., Wang, Z., Zhu, X., Wu, W., Lu, Y., Dai, Y., Wang, Z., Jiang, L., Tan, Y. Z., Liu, X., et al. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100072 · Cited by 5
Yokoyama, Y., Takashina, Y., Morel, J., Taworntawat, T., Kitamura, N., Nagano, U., Tanigaki, T., Nakamura, A., Miyazaki, T., Taoka, H., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112603 · Cited by 6
“In the present study, por-phyran administration also reduced hepatic lipid accumulation and prevented MetS, MASLD, MASH, and HCC. Conversely, it has been demonstrated that ceramide administration exacerbates obesity and insulin resistance 31 and fatty liver.”
Pathogenic mechanisms and therapeutic potential of the microbiome in premature ovarian insufficiency
Ma, S., Zheng, L., Zhuang, X., Wang, M., & Zou, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1734367 · Cited by 5
“Microbiota dysbiosis induces insulin resistance and hyperinsulinemia, stimulating excessive ovarian androgen production (107).”
Zhang, Z., Wang, S., Sun, G., & Pan, D. (2025) · Nutrients · doi:10.3390/nu18010119 · Cited by 5
“IF-induced bile acid remodeling consistently correlates with reduced hepatic glucose output and enhanced GLP-1 secretion in preclinical and small human studies [43,44,47].”
Nutrient infusion in the dorsal vagal complex controls hepatic lipid and glucose metabolism in rats
Li, R. J. W., Batchuluun, B., Zhang, S., Abraham, M. A., Wang, B., Lim, Y.-M., Yue, J. T. Y., & Lam, T. K. T. (2021) · iScience · doi:10.1016/j.isci.2021.102366 · Cited by 8
Iguchi, Y., Yamashita, Y., Gohda, K., Oda, K., Fujimori, K., Sera, Y., Imanaka, T., Yamaguchi, M., Une, M., & Teno, N. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00311 · Cited by 6
Manipulating the Microbiome: An Alternative Treatment for Bile Acid Diarrhoea
Hillman, E. B. M., Rijpkema, S. G. T., Carson, D., Arasaradnam, R. P., Wellington, E. M. H., & Amos, G. C. A. (2021) · Microbiology Research · doi:10.3390/microbiolres12020023 · Cited by 6
“The antagonistic effects of primary bile acids, taurine conjugated αMCA (TαMCA), taurine conjugated βMCA (TβMCA), glycine conjugated βMCA (GβMCA) and UDCA have been observed for FXR [91,95,127].”
BackgroundMicrobial Metabolites as Molecular Mediators of Host-Microbe Symbiosis in Colorectal Cancer
Keane, J. M., Joyce, S. A., Gahan, C. G. M., Hyland, N. P., & Houston, A. M. (2020) · Results and problems in cell differentiation · doi:10.1007/978-3-030-51849-3_22 · Cited by 5
Allobaculum plays a predominant role in the activation of brown fat tissue by diallyl trisulfide
Hu, Y., Xu, Y., Huangfu, B., Zhang, R., Xu, J., Gao, R., Wang, T., Wang, J., Huang, K., Luo, Y., et al. (2025) · Food Frontiers · doi:10.1002/fft2.456 · Cited by 4
Paraiso, I. L., Magaña, A. A., Alexiev, A., Sharpton, T. J., Maier, C. S., Kioussi, C., & Stevens, J. F. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331040 · Cited by 6
“[11,13,15] Although there is a substantial body of evidence supporting the involvement of the gut microbiome in lipid accumulation and the onset of obesity, [18] the interplay between FXR signaling, BAs and the gut microbiota is insufficiently explored.”
Wang, Y., Chen, Y., Cong, Y.-X., Wang, Y.-P., Liu, P., Du, Y.-P., Zhang, J., Wang, X.-C., Xu, T., Sinclair, A. J., et al. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110136 · Cited by 6
Xie, Y., Xie, D., Guo, S., Wang, Z., Cai, Y., Wang, X., Yang, Q., Lin, C., Yao, H., Zhao, Q., et al. (2025) · Journal of Future Foods · doi:10.1016/j.jfutfo.2025.10.017 · Cited by 4
Liang, X., Zhang, Y., Xie, W., Xiong, J., Lin, S., Wen, Y., Cao, Y., Yu, S., Wang, K., Deng, J., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02381-9 · Cited by 4
“6g–k), consistent with previous reports 28,29 .”
Self-citationWang, J., Li, H., Zhu, H., Xia, S., Zhang, F., Zhang, H., Liu, C., Zheng, W., & Yao, W. (2024) · Animals · doi:10.3390/ani14121824 · Cited by 4
“SID Lys:NE ratio facilitated IMF marbling score and serum TG level may indicate that LR diets altered host lipid Hepatic TG synthesis and secretion were central to maintaining serum TG homeostasis [18]. metabolism, especially in the liver.”
BackgroundHasan, M. N., Wang, H., Luo, W., Clayton, Y. D., Gu, L., Du, Y., Palle, S. K., Chen, J., & Li, T. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100649 · Cited by 4
“While CDCA is a potent FXR ligand, MCAs act as endogenous FXR antagonists (15).”
BackgroundMethodResultInfluentialAlhamoud, Y., Abudumijiti, T., Wu, J., Lu, L., Zhao, M., Luo, X., Feng, F., & Wang, J. (2024) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2024.104779 · Cited by 5
Yang, Y., Jiao, L., Huang, Y., Shang, H., Li, E., Chang, H., Cui, H., & Wan, Y. (2025) · Environmental Health Perspectives · doi:10.1289/ehp15435 · Cited by 4
“…FXR antagonism in intestine was reported to decrease de novo lipogenesis and improve steatosis through an FXR-ceramide-SREBP1c pathway in mice, 58,59 the expressions of ceramide synthesis genes (including Sptlc1 , Sptlc2 , Cers2 , Cers4 , Cers6 , Degs1 , Degs2 , Smpd2 , Smpd3 , and Smpd4 )…”
Wang, J., Gao, J., Zhang, Q., Lu, J., Yang, Y., Cai, X., Dong, H., & Lu, L. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17017 · Cited by 5
“However, emerging evidences suggests that targeting intestinal-selective FXR antagonists could be beneficial for weight control, decreased insulin resistance, and the alleviation of MASH through reducing ceramide level [7, 9, 31–33].”
Liu, J., Lian, G., Wang, T., Ma, Y., Zhou, J., Jiang, C., & Yin, Y. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.07.020 · Cited by 4
Self-citationFarnesoid X receptor ‐ a molecular predictor of weight loss after vertical sleeve gastrectomy?
SCOTT, F. R., Elahi, S., Adebibe, M., Parampalli, U., Mannur, K. R., Góralczyk, A., & Sanger, G. J. (2019) · Obesity Science & Practice · doi:10.1002/osp4.337 · Cited by 5
Lee, H., Cho, S., Kang, A., Shin, D., Park, H.-Y., & Jeong, T. (2021) · Life · doi:10.3390/life11070645 · Cited by 4
“Consistent with these results, intestine-specific NR1H4 inhibition or liver-specific CYP7A1 inhibition in transgenic mice showed reduced hepatic TG content but did not affect serum TG levels [34,35].”
BackgroundResultLutsiv, T., Fitzgerald, V. K., Neil, E. S., McGinley, J. N., Hussan, H., & Thompson, H. J. (2025) · Nutrients · doi:10.3390/nu17111827 · Cited by 4
“DNA oligo-primers were previously synthesized (Integrated DNA Technologies, Coralville, IA, USA) [36].”
Huang, H., Zhao, H., Wenqing, L., Xu, F., Wang, X., Yao, Y., & Huang, Y. (2024) · Medicine · doi:10.1097/md.0000000000037104 · Cited by 3
Yang, H., & Park, C. (2016) · The Korean Journal of Obesity · doi:10.7570/kjo.2016.25.4.167 · Cited by 3
“This is of notable importance because the inhibition of hepatic FXR could result in hepatic steatosis and toxicity, as seen in global FXR knockout and liver-specific FXR knockout mice.(2,17,53,55) A more recent study has demonstrated that the inhibition of intestinal FXR signals by an endogenous bile acid TβMCA or its…”
BackgroundChen, Z., Watanabe, S., Nishidono, Y., & Tanaka, K. (2020) · Traditional & Kampo Medicine · doi:10.1002/tkm2.1254 · Cited by 3
Bile Acids: A Bridge Linking Gut Microbiota and NAFLD
Zhang, J., Wang, C., Ji, X., Wu, F., Lin, Z., Zhou, Y., Xu, C., & Wang, F. (2022) · Advanced Gut & Microbiome Research · doi:10.1155/2022/4752148 · Cited by 3
“CDCA is the most efficient endogenous ligand of FXR, and other natural ligands include DCA, LCA, and CA [27].”
BackgroundIsomeric differentiation of bile acids using three‐dimensional MS2 spectrum
Niu, X., Zhou, Y., Zhao, W., Li, X., Ren, L., Tu, P., Liu, W., & Song, Y. (2024) · Journal of the Chinese Chemical Society · doi:10.1002/jccs.202300424 · Cited by 3
Gly-βMCA modulates bile acid metabolism to reduce hepatobiliary injury in Mdr2 KO mice
Hasan, M. N., Wang, H., Luo, W., Du, Y., & Li, T. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00044.2025 · Cited by 4
On the Pharmacology of Farnesoid X Receptor Agonists: Give me an "A", Like in "Acid"
Hambruch, E., Kinzel, O., & Kremoser, C. (2016) · Nuclear Receptor Research · doi:10.11131/2016/101207 · Cited by 3
A Western diet-induced mouse model reveals a possible mechanism by which metformin decreases obesity
Gonzalez, F. J., & Jiang, C. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2322-3 · Cited by 3
“nal farnesoid X receptor also leads to significant white adipose beiging promoting energy expenditure increase and weight loss [17, 18].”
Self-citationCheng, Z., Liu, T.-M., Ren, P.-F., Chen, C., Wang, Y., Dai, Y., & Zhang, X. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i31.4328 · Cited by 3
Ribeiro, M. M., Alvarenga, L., Nascimento, D., Lima, L. S., Mafra, D., & Cardozo, L. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01116-4 · Cited by 2
“Changes in the gut microbiota may modulate intestinal ceramide biosynthesis through farnesoid X receptor (FXR) signaling by activating FXR target genes involved in ceramide synthesis, such as Sptlc2 and Smpd3 mRNA [32, 33].”
Integrating bile acid metabolism into precision nutrition strategies for improved swine performance
Li, S., He, Y., Shaoyong, W., Wang, Y., & Jin, M. (2025) · Animal nutrition · doi:10.1016/j.aninu.2025.05.013 · Cited by 3
Du, B., Cheng, C., Feng, J., Liang, Y., Tao, W., Xu, B., Peng, J., Zhang, G., & Yang, Y. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71321 · Cited by 2
“…LPS translocation activating Kupffer cells (Cani et al. 2007; Wiest et al. 2017); (2) altered bile acid metabolism affecting FXR signaling (Jiang et al. 2015; Sayin et al. 2013); and (3) diminished SCFA-mediated anti-inflammatory effects via G- protein-coupled receptors (Kimura et al.…”
Zhang, J., Jiang, D., Zhang, X., Yang, Y., & Wu, Z. (2026) · Food Research International · doi:10.1016/j.foodres.2026.118797 · Cited by 2
Xin-yi, Z. H. A. O., Chang, T., Wu, X., Huo, T., Peng, J., Liu, Y., Li, D., Wang, C., Yang, F., Wang, J., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.038 · Cited by 3
Self-citationMeng, Y., Li, S., Zhou, K., Suonan, Z., Dai, Z., Shen, Q., & Xue, Y. (2026) · Food Chemistry · doi:10.1016/j.foodchem.2026.149195 · Cited by 2
Wang, X. J., Cheng, L., Yin, K., Wang, B., Yan, X., & Chen, S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08448-9 · Cited by 5
“We observed a similar protective effect on stem cell self-renewal and intestinal repair using Gly-β-MCA, an intestine-specific FXR antagonist, known to improve metabolic dysfunction [55].”
An approach to gene-based testing accounting for dependence of tests among nearby genes
Yurko, R., Roeder, K., Devlin, B., & G’Sell, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab329 · Cited by 2
Leveraging the Microbiome for Obesity: Moving From Form to Function
Lee, A. H., Manly, A., & Dong, T. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.918923 · Cited by 2
“FXR antagonism by BAs such as glycine-b-muricholic acid (Gly-MCA) and TBMCA in intestinal cells has been associated with prevention of obesity (32, 35), with similar effects seen from mice with intestinal FXR KO genes (36).”
BackgroundChen, W., Zhou, S., Xiao, J., Liu, W. Y., Qu, Q., & He, X. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.80563 · Cited by 2
“Mice with intestinal-selective FXR inhibition showed protection from the development of glucose intolerance and obesity [18].”
InfluentialDietary prevention of antibiotic‐induced dysbiosis and mortality upon aging in mice
Smith, K., Francisco, S. G., Zhu, Y., LeRoith, T., Davis, M. L., Crott, J. W., Barger, K., Greenberg, A. S., Smith, D. E., Taylor, A., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202402262r · Cited by 2
“63 Analysis of tryptophan metabolism potential in HGAbx mice compared to control mice and LGAbx mice revealed an increase in kynurenine degradative pathways and a decrease in indole degradative pathways.”
Integrating deep learning and molecular dynamics simulations for FXR antagonist discovery
Yang, Y., Huang, Y., Shen, H., Wang, D., Liu, Z., Zhu, W., & Liu, Q. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11145-2 · Cited by 2
“As a central sensor and regulator, FXR orchestrates the biosynthesis and enterohepatic recycling of endogenous bile acids (BAs) [4–6].”
Managing Glucose Homeostasis Through the Gut Microbiome
Weninger, S. N., Manley, A., & Duca, F. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-051524-094728 · Cited by 4
Verdauungsoptimierung – wie sich Ernährung und Mikrobiom gegenseitig beeinflussen
Bischoff, S. C. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0826-1977 · Cited by 2
“Der gestörte Gallensäuren-Metabolismus verstärkt die MikrobiomVeränderungen, weshalb Farneosid-X-Rezeptor (FXR)-Inhibitoren zur Behandlung dieser Pathologie erfolgreich untersucht wurden [19].”
BackgroundGutting out Myc to decrease ceramides
Li, Y., Summers, S. A., & Holland, W. L. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00418-3 · Cited by 2
Reduction of intestinal RIPK1 ameliorates HFD-induced metabolic disorders in female mice
Yuan, Y., Hu, X., Guo, C., Xu, Y., Li, S., Wen, W., Hu, X., Zeng, F., Cui, W., Chen, W., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111906 · Cited by 2
“8 11 And these distinct gene expression profiles, stem cell proliferation, and differentiation can be altered in high-fat/high-sugar diet-induced obese mice.”
Hasan, M. N., Wang, H., Luo, W., Du, Y., Xiong, L., Gu, L., & Li, T. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100936 · Cited by 1
“More recently, we have uncovered a potent anticholestasis effect of glycine-conjugated β -MCA (Gly-β MCA) (23, 24), a hydrophilic bile acid derivative that was identified by molecular modeling as a gut-restricted FXR antagonist with antiobesity and insulin-sensitizing properties (25).”
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Su, L., Huo, T., Zhao, X., Pang, Z., Wang, T., Liu, Y., Dou, X., & Jiao, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03064 · Cited by 1
Self-citationBaeuerle, E., Semwal, M. K., Nie, J., Zhang, N., Liang, H., Ganapathy, V., Sathavarodom, N., Fernandez, R., Wang, C. P., Espinoza, S., et al. (2026) · Obesity · doi:10.1002/oby.70224 · Cited by 1
“Inhibition of intestinal FXR has been shown to have beneficial impacts on insulin sensitivity in animal models of obesity [36].”
The interplay between the microbiome and immune cells in metabolic homeostasis and disease
Shapiro, H., Jickeli, B., Niv, I., Ernan, B., & Elinav, E. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.004 · Cited by 7
Metadata
- Authors
- Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Pennsylvania State University (US)
- Oregon State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-12-15
- Volume
- 6
- Issue
- 1
- Pages
- 10166-10166
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4682112
- OpenAlex
- W2236340720
- Cited by
- 559
- References
- 58
- Citations by year
- 2026: 33 · 2025: 55 · 2024: 54 · 2023: 49 · 2022: 56 · 2021: 78 · 2020: 61 · 2019: 52 · 2018: 39 · 2017: 49 · 2016: 32
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Greater South Information System
- Funders
- Pennsylvania Department of Health
- National Natural Science Foundation of China (31401011, 81200626)
- National Institutes of Health
- National Cancer Institute
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- farnesoid X receptor, obesity, insulin resistance, hepatic steatosis, ceramide biosynthesis, high-fat diet-induced obesity, bile acid metabolism, GW4064, ileum, metabolic dysfunction
- MeSH terms
- Receptor, Farnesoid X-Activated, Adolescent, Adult, Aged, Animals, Ceramides, Cholic Acids, Fatty Liver, Female, Glycine, Humans, Ileum, Insulin Resistance, Intestinal Mucosa, Isoxazoles, Liver, Male, Middle Aged, Obesity, Receptors, Cytoplasmic and Nuclear, Mice, Young Adult, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.